History of lung transplantation P. Corris (Newcastle upon Tyne, United Kingdom)
| |
History of lung transplantation in Turkey G. Dabak (Istanbul, Turkey)
| |
The key elements of a lung transplant programme J. Gottlieb (Hannover, Germany)
| |
Referral guidelines and specific criteria for candidate selection in CF, ILD, COPD and PH G. Verleden (Leuven, Belgium)
| |
Candidate selection and management: specific controversial and ethical issues R. Vos (Leuven, Belgium)
| |
Paediatric candidates: special issues C. Benden (Zurich, Switzerland)
| |
Pushing the boundaries of usable donors: marginal donors A. Fisher (Newcastle upon Tyne, United Kingdom)
| |
Size reduction and living lobar transplantation G. Massard (Strasbourg, France)
| |
Non heart-beating donors D. Van Raemdonck (Leuven, Belgium)
| |
Ex-vivo donor lung perfusion D. Van Raemdonck (Leuven, Belgium)
| |
PGD physiopathology, prevention and treatment G. Verleden (Leuven, Belgium)
| |
Acute cellular and humoral rejection F. Meloni (Pavia, Italy)
| |
Airway complication after lung transplantation G. Massard (Strasbourg, France)
| |
What’s new in induction therapy P. Corris (Newcastle upon Tyne, United Kingdom)
| |
Standard IS regimens: CNI is still the cornerstone R. Vos (Leuven, Belgium)
| |
Alternative immunosuppressive strategies J. Gottlieb (Hannover, Germany)
| |
Prevention and treatment of viral infections: CMV and other community respiratory viruses E. Verschuuren (Groningen, Netherlands)
| |
Aspergillus and other fungi G. Verleden (Leuven, Belgium)
| |
Bacterial infections A. Fisher (Newcastle upon Tyne, United Kingdom)
| |
Complications in paediatric lung transplantation C. Benden (Zurich, Switzerland)
| |
CLAD or BOS? : classification and pathogenesis G. Verleden (Leuven, Belgium)
| |
How to diagnose and manage CLAD: immunosuppressive/modulatory strategies A. Fisher (Newcastle upon Tyne, United Kingdom)
| |
Treatment of risk factors J. Gottlieb (Hannover, Germany)
| |
Retransplantation for CLAD: indications, outcomes and ethical issues G. Massard (Strasbourg, France)
| |
Renal dysfunction and cardiovascular disorders F. Meloni (Pavia, Italy)
| |
Lymphoproliferative disease and other malignancies E. Verschuuren (Groningen, Netherlands)
| |